WCLC 2022 | SQUINT: nivolumab+ipilimumabi v platinum-based CT+nivolumab in advanced lung squamous cell carcinoma
Federico Cappuzzo, MD, PhD, AUSL della Romagna-Ravenna, Ravenna, Italy, discusses the results of the Phase II SQUINT (NCT03823625) trial, comparing the efficacy of nivolumab in combination with ipilimumab versus platinum-based chemotherapy plus nivolumab in patients with advanced or metastatic lung squamous cell carcinoma. The primary endpoint was overall-survival (OS) at 12 months. The 1-year OS rate was 59.1% versus 62.4% for nivolumab monotherapy versus nivolumab plus chemotherapy, respectively. Median progression-free survival (PFS) was 3.8 months with nivolumab compared to 6.1 months with chemotherapy plus nivolumab and response rate was 22.2% and 30.4%, respectively. Long-term survival at 18-months and 24-months was almost double in the group of patients receiving nivolumab in combination with ipilimumab. Interestingly, patients with bone metastasis that are usually observed be more resistant to immunotherapy showed a significant benefit with the combination of nivolumab with ipilimumab. Additional analysis for biomarkers is ongoing. This interview took place at the IASLC 2022 World Conference on Lung Cancer congress in Vienna, Austria.
Transcript (edited for clarity)
The SQUINT trial was a Phase II randomized trial comparing two different regimen specifically in patients with squamous histology, with metastatic disease. Patients were randomized to a treatment of nivolumab plus ipilimumab, so a chemo-free combination, versus the combination of chemotherapy and nivolumab. The data were presented at this meeting. And in this trial, we showed no difference between the two arms in terms of median PFS and median OS, but long-term survival, so survival at 18 months and survival at 2 years, was almost double in the group of patients receiving the combination of nivolumab and ipilimumab...
The SQUINT trial was a Phase II randomized trial comparing two different regimen specifically in patients with squamous histology, with metastatic disease. Patients were randomized to a treatment of nivolumab plus ipilimumab, so a chemo-free combination, versus the combination of chemotherapy and nivolumab. The data were presented at this meeting. And in this trial, we showed no difference between the two arms in terms of median PFS and median OS, but long-term survival, so survival at 18 months and survival at 2 years, was almost double in the group of patients receiving the combination of nivolumab and ipilimumab. Also, interestingly, in this trial, we observed that patients with bone mets that classically are patients more resistant to immunotherapy and with a worse prognosis, had a significant benefit with the combination of nivolumab plus ipilimumab. Additional analysis are ongoing for biomarkers and will be presented at next meetings.
Read more...
